Joseph J Eron

Joseph J Eron's AcademicInfluence.com Rankings

Joseph J Eron

Philosophy

#5632

World Rank

#8491

Historical Rank

Logic

#2869

World Rank

#3939

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Joseph J Eron Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joseph J Eron's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. (1997) (2544)
Prevention of HIV-1 infection with early antiretroviral therapy. (2011) (2213)
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. (1997) (1911)
Effect of early versus deferred antiretroviral therapy for HIV on survival. (2009) (1170)
Antiretroviral Therapy for the Prevention of HIV-1 Transmission. (2016) (1154)
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
Antiretroviral Treatment of Adult HIV Infection (2008) (1090)
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1 (1997) (902)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. (2003) (885)
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. (2008) (828)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. (2016) (753)
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. (2012) (742)
Brief but efficient: acute HIV infection and the sexual transmission of HIV. (2004) (728)
Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia (2008) (610)
Raltegravir with optimized background therapy for resistant HIV-1 infection. (2008) (570)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. (2008) (544)
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. (1995) (532)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel (2018) (527)
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. (2014) (445)
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. (2014) (435)
Detection of acute infections during HIV testing in North Carolina. (2005) (392)
Maximizing sensitivity and specificity of PCR by pre-amplification heating (1991) (368)
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial (2006) (358)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial (2017) (339)
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men (2010) (329)
Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. (2015) (324)
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. (2015) (322)
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model (2001) (321)
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials (2010) (311)
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV (2000) (308)
The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial (2010) (307)
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy (2009) (296)
Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. (2000) (295)
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study (2014) (286)
The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. (1999) (278)
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study (2012) (273)
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. (1998) (255)
Novel therapies based on mechanisms of HIV-1 cell entry. (2003) (254)
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results (2001) (252)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. (2020) (246)
Selection Bias Due to Loss to Follow Up in Cohort Studies. (2016) (232)
HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. (2014) (229)
Prevalence of DSM-IV-Defined Mood, Anxiety, and Substance Use Disorders in an HIV Clinic in the Southeastern United States (2006) (225)
Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants (1999) (223)
Quantification of HIV in semen: correlation with antiviral treatment and immune status (1997) (221)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (2019) (221)
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection (2012) (216)
Late presentation for human immunodeficiency virus care in the United States and Canada. (2010) (215)
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. (2010) (200)
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. (2016) (198)
3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine (2000) (198)
Macrophages sustain HIV replication in vivo independently of T cells. (2016) (195)
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. (2002) (194)
Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study (2013) (193)
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. (2002) (192)
Psychiatric Illness and Virologic Response in Patients Initiating Highly Active Antiretroviral Therapy (2007) (192)
Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. (2005) (192)
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. (2011) (191)
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients (1996) (189)
Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis (2013) (189)
Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide (2014) (188)
Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers (2006) (186)
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health (2001) (184)
Acute HIV revisited: new opportunities for treatment and prevention. (2004) (182)
Resistance of HIV‐1 to antiretroviral agents in blood and seminal plasma: implications for transmission (1998) (179)
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). (2007) (178)
Effect of antiviral treatment on the shedding of HIV‐1 in semen (1997) (178)
Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. (2002) (175)
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells (2008) (175)
Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection (2009) (173)
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. (2015) (166)
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy (2017) (166)
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (2021) (163)
Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis (2012) (163)
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase (1994) (158)
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials (2005) (156)
Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection (2010) (155)
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. (2002) (153)
End-stage renal disease among HIV-infected adults in North America. (2015) (151)
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy (2003) (151)
Splines for trend analysis and continuous confounder control. (2011) (151)
Frequent detection of acute primary HIV infection in men in Malawi (2004) (150)
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262) (2011) (147)
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. (2001) (145)
Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection (2010) (144)
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus (2021) (143)
Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. (1995) (140)
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. (1999) (139)
Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections (2011) (139)
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency (2017) (138)
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation (2017) (135)
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. (2013) (134)
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. (2001) (134)
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. (2011) (134)
Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies (2013) (133)
Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. (2013) (133)
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification (2008) (132)
HIV Antigens Can Induce TGF-β1-Producing Immunoregulatory CD8+ T Cells1 (2002) (132)
Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality. (2014) (130)
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care (2012) (129)
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals (2008) (128)
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. (2004) (126)
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. (2013) (125)
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings (2012) (125)
Pharmacokinetics of lamivudine administered alone and with trimethoprim‐sulfamethoxazole (1996) (125)
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. (2011) (121)
GENDER DIFFERENCE IN HIV RNA LEVELS: A META-ANALYSIS OF PUBLISHED STUDIES (2002) (121)
Multiple V1/V2 env Variants Are Frequently Present during Primary Infection with Human Immunodeficiency Virus Type 1 (2004) (120)
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. (2019) (120)
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy (1993) (120)
Prevalence and Comorbidity of Psychiatric Diagnoses Based on Reference Standard in an HIV+ Patient Population (2008) (118)
Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States (2017) (116)
Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States (2018) (115)
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. (2013) (112)
Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. (2003) (111)
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial (2018) (110)
Sexual transmission during the incubation period of primary HIV infection. (2001) (110)
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? (2011) (108)
No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy (2012) (107)
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. (2004) (107)
Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. (1991) (106)
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. (2011) (104)
Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1 (2000) (103)
Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. (2014) (100)
Detection and biologic characterization of infectious HIV-1 in semen of seropositive men (1994) (100)
Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems (2017) (99)
Effects of Genital Tract Inflammation on Human Immunodeficiency Virus Type 1 V3 Populations in Blood and Semen (2000) (96)
Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population (2017) (94)
Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction (2004) (92)
Generalizing evidence from randomized trials using inverse probability of sampling weights (2018) (92)
Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells (2011) (91)
HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. (1996) (91)
Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. (2010) (89)
Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance (2005) (89)
HIV-1 Drug Resistance Evolution Among Patients on Potent Combination Antiretroviral Therapy With Detectable Viremia (2005) (89)
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)* (2000) (88)
Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment (2017) (88)
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis (2000) (88)
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. (2006) (87)
CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? (2010) (86)
Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients (2012) (85)
Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks (2005) (85)
HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015 (2018) (84)
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. (1999) (83)
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. (2003) (83)
Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. (2011) (82)
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials (2019) (81)
Oral manifestations of HIV in a southeast USA population. (2008) (80)
Vasculitic and encephalitic complications associated with Coccidioides immitis infection of the central nervous system in humans: report of 10 cases and review. (1992) (80)
Curing HIV: Seeking to Target and Clear Persistent Infection (2020) (79)
Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy (2011) (78)
Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1 (1999) (78)
Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. (2019) (76)
Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. (2019) (76)
Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. (1999) (75)
An HIV Self-Care Symptom Management Intervention for African American Mothers (2003) (74)
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. (2016) (74)
Factors associated with fewer visits for HIV primary care at a tertiary care center in the SoutheAstern U.S. (2006) (73)
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. (2010) (71)
Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients (2008) (71)
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, (2018) (71)
Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. (2013) (70)
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). (2000) (70)
HIV-1 Protease, Reverse Transcriptase, and Integrase Variation (2016) (68)
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine (2003) (68)
Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals (2004) (67)
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients (2018) (67)
Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study (2010) (67)
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection (2000) (66)
Prevalence of Transmitted Antiretroviral Drug Resistance Differs Between Acutely and Chronically HIV-Infected Patients (2012) (66)
Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection (1996) (66)
HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. (2002) (65)
HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers (2016) (65)
Phylogenetic insights into regional HIV transmission (2012) (65)
Perceived oral health status, unmet needs, and barriers to dental care among HIV/AIDS patients in a North Carolina cohort: impacts of race. (2007) (64)
Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome (2001) (64)
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. (2009) (64)
Frequent detection of acute HIV infection in pregnant women (2007) (63)
CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection (2012) (62)
Reductions in HIV‐1 disease progression for zidovudine/lamivudine relative to control treatments: a meta‐analysis of controlled trials (1997) (62)
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro (1992) (61)
Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America (2017) (59)
High Levels of Antiretroviral Use and Viral Suppression Among Persons in HIV Care in the United States, 2010 (2013) (58)
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. (2008) (58)
Joint effects of alcohol consumption and high-risk sexual behavior on HIV seroconversion among men who have sex with men (2013) (58)
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo (1993) (58)
Investigating a Sexual Network of Black Men Who Have Sex With Men: Implications for Transmission and Prevention of HIV Infection in the United States (2012) (57)
Validation of a Brief Screening Instrument for Substance Abuse and Mental Illness in HIV-Positive Patients (2005) (57)
Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation (2013) (56)
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. (2020) (55)
Improving health outcomes among individuals with HIV, mental illness, and substance use disorders in the Southeast (2006) (55)
The Detection and Management of Early HIV Infection: A Clinical and Public Health Emergency (2013) (55)
Types of Myocardial Infarction Among Human Immunodeficiency Virus–Infected Individuals in the United States (2017) (55)
Clones of infected cells arise early in HIV-infected individuals. (2019) (54)
Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection (2006) (54)
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. (1999) (54)
Effect of pulmonary tuberculosis on mortality in patients receiving HAART (2009) (53)
HIV-1 protease inhibitors. (2000) (52)
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007 (2008) (52)
Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy (2007) (51)
Expression of p16INK4a as a biomarker of T‐cell aging in HIV‐infected patients prior to and during antiretroviral therapy (2012) (51)
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. (2007) (51)
Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. (2010) (51)
Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. (2010) (49)
Substance Abuse and Symptoms of Mental Illness Among HIV-positive Persons in the Southeast (2005) (49)
Moving forward in HIV-associated cancer. (2014) (49)
Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients (2004) (49)
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. (2020) (49)
Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. (2002) (48)
A brief mental health and substance abuse screener for persons with HIV. (2005) (48)
Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast (2009) (47)
The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. (2016) (47)
Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy. (2015) (47)
Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors (2006) (47)
Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia. (2014) (46)
Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis (2016) (46)
HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. (2014) (46)
Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients (2007) (46)
Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. (2016) (45)
HIV-1 RNA Detected in the CNS after Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. (2019) (45)
Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients (2004) (45)
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. (2007) (44)
Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. (2015) (44)
Comparison of NucliSens and Roche Monitor Assays for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma (1999) (43)
Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials (1999) (43)
Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV (2018) (43)
Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain. (2015) (42)
Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. (2017) (41)
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. (2015) (41)
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). (2002) (40)
Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. (2004) (40)
Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. (1999) (39)
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. (2011) (38)
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. (1991) (38)
Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation (2004) (38)
Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy (2014) (38)
Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence (2006) (38)
Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. (2014) (38)
Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013. (2016) (38)
Acute HIV-1 infection in the Southeastern United States: a cohort study. (2013) (38)
Association of early HIV viremia with mortality after HIV-associated lymphoma (2013) (37)
Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009 (2013) (37)
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients (2002) (36)
Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. (2014) (36)
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. (2016) (35)
T cells establish and maintain CNS viral infection in HIV‐infected humanized mice (2018) (35)
HIV primary care providers--Screening, knowledge, attitudes and behaviors related to alcohol interventions. (2016) (35)
Potential Impact of Antiretroviral Therapy and Screening on Cervical Cancer Mortality in HIV-Positive Women in Sub-Saharan Africa: A Simulation (2011) (34)
Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010 (2012) (34)
Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. (1998) (34)
Social Network–Based Recruitment Successfully Reveals HIV-1 Transmission Networks Among High-Risk Individuals in El Salvador (2013) (34)
T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy (2017) (34)
Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study (2017) (33)
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection (2011) (33)
Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006–2009 (2016) (33)
HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. (2018) (33)
Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals (1997) (32)
Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. (2016) (32)
Immunosuppression, Hepatitis C Infection, and Acute Renal Failure in HIV-Infected Patients (2006) (31)
The treatment of antiretroviral‐naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials (1996) (31)
Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates. (1992) (31)
Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States. (2015) (30)
African American race and HIV virological suppression: beyond disparities in clinic attendance. (2014) (29)
Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection (2014) (29)
Pneumocystis and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma (2020) (29)
Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation (2018) (28)
Effects of Combination Antiretroviral Therapies on the Risk of Myocardial Infarction Among HIV Patients (2014) (28)
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. (2013) (28)
Social support and delays seeking care after HIV diagnosis, North Carolina, 2000–2006 (2009) (27)
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants (2017) (27)
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. (2004) (27)
Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. (2019) (27)
Emotional Distress in African American Women with HIV (2007) (27)
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TA (2019) (26)
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077 (2020) (26)
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. (2019) (26)
Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011 (2013) (26)
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. (1993) (25)
Ongoing HIV Transmission and the HIV Care Continuum in North Carolina (2015) (25)
Predictors of Residual Viraemia in Patients on Long-Term Suppressive Antiretroviral Therapy (2012) (25)
Addition of 7 Days of Zidovudine Plus Lamivudine to Peripartum Single-Dose Nevirapine Effectively Reduces Nevirapine Resistance Postpartum in HIV-Infected Mothers in Malawi (2010) (25)
Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV‐1‐Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy (2000) (24)
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV (2020) (24)
Ten Years of Screening and Testing for Acute HIV Infection in North Carolina (2016) (24)
Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077. (2020) (23)
Risk of End‐Stage Renal Disease in HIV‐Positive Potential Live Kidney Donors (2017) (23)
Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States (2018) (23)
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection (2020) (23)
Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2 (2011) (23)
Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy (2007) (23)
Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. (2013) (23)
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients (2005) (23)
Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort (2014) (23)
HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy (2021) (23)
HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States (2013) (23)
Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART (2018) (23)
High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible? (2012) (23)
Total daily pill burden in HIV-infected patients in the southern United States. (2014) (22)
Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy (2001) (22)
The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review (2014) (22)
Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. (1999) (22)
Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation. (2016) (22)
Virologic outcomes in early antiretroviral treatment: HPTN 052 (2017) (22)
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence (2014) (21)
Chagasic encephalitis as the initial manifestation of AIDS. (2006) (21)
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. (2019) (21)
Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center (2020) (21)
The Pharmacokinetics, Safety, and Initial Virologic Response of a Triple–Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir (2004) (21)
Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens (2014) (20)
HIV Care Initiation Delay Among Rural Residents in the Southeastern United States, 1996 to 2012 (2017) (20)
Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection (2003) (20)
Sexually transmitted infections among patients with acute HIV in North Carolina. (2009) (20)
Rising prevalence of non-B HIV-1 subtypes in North Carolina and evidence for local onward transmission (2017) (20)
HIV-1 Protease Inhibitors and Clinical Malaria: a Secondary Analysis of the AIDS Clinical Trials Group A5208 Study (2011) (20)
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370 (2000) (20)
The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans. (2014) (20)
HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? (2014) (20)
Naïve T Cells Are Maintained in the Periphery During the First3 Months of Acute HIV-1 Infection: Implications for Analysis of Thymus Function (2005) (19)
Does HAART Efficacy Translate to Effectiveness? Evidence for a Trial Effect (2011) (19)
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors (2015) (19)
Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care (2013) (19)
HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data. (2015) (19)
Social support and delays seeking care after HIV diagnosis (2009) (19)
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961) (2010) (19)
Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. (2009) (19)
Longitudinal dynamics of intact HIV proviral DNA and outgrowth virus frequencies in a cohort of ART-treated individuals. (2020) (19)
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy (1993) (19)
Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. (2009) (19)
Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. (2010) (19)
Major Coexisting Human Immunodeficiency Virus Type 1 env Gene Subpopulations in the Peripheral Blood Are Produced by Cells with Similar Turnover Rates and Show Little Evidence of Genetic Compartmentalization (2009) (19)
Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. (2000) (18)
New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations (2018) (18)
Loss to Clinic and Five-Year Mortality among HIV-Infected Antiretroviral Therapy Initiators (2014) (18)
Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010. (2012) (18)
Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study (2013) (18)
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. (2002) (18)
Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS) (2019) (18)
Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience (2008) (18)
High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response (2007) (18)
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART (2018) (17)
Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation (2017) (17)
Prediction of HIV Transmission Cluster Growth With Statewide Surveillance Data (2019) (17)
Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks (2018) (17)
Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin. (2009) (17)
Elevated AST‐to‐platelet ratio index is associated with increased all‐cause mortality among HIV‐infected adults in Zambia (2015) (17)
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. (2001) (17)
Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy (2017) (17)
Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir (2001) (16)
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. (2001) (16)
Multiple Imputation to Account for Measurement Error in Marginal Structural Models (2015) (16)
Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort (2018) (16)
24 Genomic sequences and quasi-multivariate CATANOVA (2000) (16)
Neurocognition with maraviroc compared with tenofovir in HIV (2016) (16)
Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry. (2002) (16)
Hospitalization Rates and Outcomes among Persons Living with HIV in the Southeastern United States, 1996-2016. (2020) (15)
Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort (2015) (15)
The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment (2012) (15)
Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. (2008) (15)
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study (2016) (15)
US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. (2017) (15)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. (2022) (14)
Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial (2016) (14)
Impact of biological sex on immune activation and frequency of the latent HIV reservoir during suppressive antiretroviral therapy. (2020) (14)
Age trends in the prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Cameroon: a cross-sectional study (2012) (14)
Hepatic Safety and Tolerability of Raltegravir among HIV Patients Coinfected with Hepatitis B And/Or C (2014) (14)
Using Primer-ID Deep Sequencing to Detect Recent Human Immunodeficiency Virus Type 1 Infection (2018) (14)
Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells (2019) (14)
Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. (2007) (14)
Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study (2020) (14)
Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study (2012) (14)
PD-1HI T cells are associated with lower hiv-specific immune responses despite long-term antiretroviral therapy. (2019) (14)
The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care (2017) (14)
Incident Sexually Transmitted Infection as a Biomarker for High-Risk Sexual Behavior After Diagnosis of Acute HIV (2014) (13)
Increased Cortical Cerebral Blood Flow in Asymptomatic Human Immunodeficiency Virus-Infected Subjects. (2016) (13)
A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir (2002) (13)
Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care (2006) (13)
Spatial Epidemiology of Recently Acquired HIV Infections across Rural and Urban Areas of North Carolina (2014) (13)
HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. (2010) (13)
Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. (2017) (13)
Discontinuation Rates for Protease Inhibitor Regimens Containing Ritonavir 600 mg versus Ritonavir 400 mg Plus Saquinavir 400 mg (1999) (13)
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095 (2012) (13)
Self‐report of current and prior antiretroviral drug use in comparison to the medical record among HIV‐infected patients receiving primary HIV care (2011) (13)
Large scale screening of human sera for HCV RNA and GBV‐C RNA (2014) (12)
No Evidence for an Association between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART (2019) (12)
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 (2022) (12)
The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals (2017) (12)
Identifying HIV care enrollees at-risk for cannabis use disorder (2017) (12)
Variability of the date of HIV diagnosis: a comparison of self-report, medical record, and HIV/AIDS surveillance data. (2010) (12)
Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care (2013) (12)
Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. (2011) (12)
Viral and Symptom Rebound in Untreated COVID-19 Infection (2022) (11)
Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens (2017) (11)
Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load. (2020) (11)
Phylogenetic Evidence of HIV-1 Sequence Evolution in Subjects with Persistent Low-Level Viraemia (2015) (11)
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals (2019) (11)
R5 Macrophage-Tropic HIV-1 in the Male Genital Tract (2015) (11)
The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients. (2013) (11)
One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States (2018) (11)
Residual Plasma Viraemia and Infectious HIV-1 Recovery from Resting Memory CD4 Cells in Patients on Antiretroviral Therapy: Results from ACTG A5173 (2013) (11)
Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction (2019) (11)
Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020 (2022) (11)
Simplifying antiretroviral therapy. (2004) (11)
Faculty Opinions recommendation of Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. (2012) (11)
Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-week Results of AIDS Clinical Trials Group A5241 (OPTIONS). (2019) (10)
Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020 (2021) (10)
Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era. (2020) (10)
HIV-1 Phylodynamics to Detect and Characterize Active Transmission Clusters in North Carolina. (2019) (10)
How Researchers Define Vulnerable Populations in HIV/AIDS Clinical Trials (2010) (10)
Pre-treatment integrase strand transfer inhibitor resistance in north carolina from 2010-2016. (2017) (10)
Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States (2017) (10)
Faculty Opinions recommendation of Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. (2012) (10)
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir (2016) (10)
HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated with HIV DNA and HIV-specific T Cell Responses. (2019) (10)
Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. (2013) (10)
Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016. (2017) (10)
Pilot study demonstrating effectiveness of targeted education to improve informed consent understanding in AIDS clinical trials (2011) (9)
HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052 (2017) (9)
Erratum: Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection (AIDS (2000) 14 (671-681)) (2000) (9)
Antiretroviral therapy: new drugs, formulations, ideas, and strategies. (2009) (9)
Dose Separation Does Not Overcome the Pharmacokinetic Interaction between Fosamprenavir and Lopinavir/Ritonavir (2006) (9)
Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection (2015) (9)
Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders* (2017) (9)
Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients (2017) (9)
Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015. (2020) (9)
Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015. (2020) (9)
The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine. (2007) (9)
Viral suppression in HIV studies: Combining times to suppression and rebound (2014) (9)
LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients (2021) (9)
Advances in antiretroviral therapy (2013) (9)
Genetic architecture of cardiometabolic risks in people living with HIV (2020) (9)
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. (2004) (9)
Brief Report: Longitudinal Opioid Use Among HIV-Infected Patients, 2000 to 2014 (2017) (9)
Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. (2017) (9)
Drug and alcohol use among people living with HIV in care in the United States by geographic region (2021) (8)
Modeling Clinical Endpoints as a Function of Time of Switch to Second‐Line ART with Incomplete Data on Switching Times (2013) (8)
Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy (2018) (8)
Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. (2020) (8)
Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework (2018) (8)
Ending the evidence gap for pregnancy, HIV and co‐infections: ethics guidance from the PHASES project (2021) (8)
Outpatient Treatment of SARS-CoV-2 Infection to Prevent COVID-19 Progression (2021) (8)
Health Insurance Type and Control of Hypertension Among US Women Living With and Without HIV Infection in the Women’s Interagency HIV Study (2017) (8)
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race–ethnicity determine the degree of regimen complexity (2015) (8)
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. (2021) (8)
Mortality Among Persons Entering HIV Care Compared With the General U.S. Population (2021) (8)
Patterns of Efavirenz use as First-Line Antiretroviral Therapy in the United States: 1999–2015 (2018) (8)
Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy (2009) (8)
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19 (2021) (7)
The Impact of Implementation Fidelity on Mortality Under a CD4-Stratified Timing Strategy for Antiretroviral Therapy in Patients With Tuberculosis. (2015) (7)
Antiretroviral Activity and Safety of Once-Daily Etravirine in Treatment-Naive HIV-Infected Adults: 48-Week Results (2016) (7)
Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States. (2013) (7)
Illustration of a Measure to Combine Viral Suppression and Viral Rebound in Studies of HIV Therapy (2015) (7)
Comparing neighborhood and state contexts for women living with and without HIV: understanding the Southern HIV epidemic (2018) (7)
Paradoxical interpretations of noninferiority studies: violating the excluded middle (2012) (6)
Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy (2013) (6)
Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV. (2017) (6)
Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. (2007) (6)
LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care (2019) (6)
Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008-2015. (2020) (6)
Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression (2021) (6)
Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761) (2014) (6)
Postpartum HIV care continuum outcomes in the southeastern USA (2019) (6)
Dynamic Visual Display of Treatment Response in HIV-Infected Adults. (2015) (6)
Alternative strategies for anti-HIV treatment. (2001) (6)
Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV (2021) (6)
Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV (2018) (6)
Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017. (2020) (6)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study (2019) (5)
Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections (2016) (5)
Entry and Fusion Inhibitors: an Update (2002) (5)
Fusion designs and estimators for treatment effects (2021) (5)
Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the US. (2019) (5)
Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996–2016 (2020) (5)
Aciclovir treatment for human immunodeficiency virus-1: is the “juice worth the squeeze?”. (2011) (5)
Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings (2019) (5)
Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting (2019) (5)
AIDS Defining Conditions (ADCs) in the BENCHMRK -1 and -2 trials: 48 Week Analysis (2008) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Erratum: Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1 (Antimicrobial Agents and Chemotherapy (1999) 43:8 (1857-1826)) (2000) (5)
Factors Associated with Delayed Hepatitis B Viral Suppression on Tenofovir Among HBV-HIV Coinfected Patients in the CNICS Cohort (2014) (5)
Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. (2012) (5)
New anti-HIV-1 therapies and combinations: current data and prospects. (1990) (5)
A novel codon insert in protease of clade B HIV type 1. (2009) (5)
Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment‐naïve HIV‐infected individuals (2012) (5)
High clade C HIV-1 viremia: how did we get here and where are we going? (2011) (4)
Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death (2020) (4)
Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons With Acute HIV Infection: Opportunity for Interrupting Transmission (2018) (4)
Brief Report: Differences in Types of Myocardial Infarctions Among People Aging With HIV. (2021) (4)
Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula (2018) (4)
Cervical cancer epidemiology among HIV-infected women in North America (2010) (4)
Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Women Without HIV. (2017) (4)
Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma. (2020) (4)
Eff ects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection : results from the phase 3 HPTN 052 randomised controlled trial (2014) (4)
HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy (2021) (4)
Untreated HCV in HIV/HCV co-infection: Data from the TRIO network (2018) (4)
Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies (2019) (4)
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events (2018) (4)
Clinical effectiveness of integrase strand transfer inhibitor-based antiretroviral regimens among adults with human immunodeficiency virus: a collaboration of cohort studies in the United States and Canada. (2020) (4)
Near Real-Time Identification of Recent Human Immunodeficiency Virus Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by Multiplexed Primer ID–Next-Generation Sequencing in North Carolina (2020) (4)
Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women’s Interagency HIV Study (2020) (4)
Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability (2016) (4)
Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States. (2013) (4)
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection (2021) (4)
Intact proviral DNA levels decline in people with HIV on antiretroviral therapy (2019) (3)
Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm (2016) (3)
The authors reply. (2014) (3)
Predicting Efavirenz Concentrations in the Brain Tissue of HIV‐Infected Individuals and Exploring their Relationship to Neurocognitive Impairment (2019) (3)
Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy (2021) (3)
Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. (2021) (3)
Novel Criteria for Diagnosing Acute and Early HIV Infection in a Multi-National Study of Early Antiretroviral Therapy Initiation. (2020) (3)
Viral Hepatitis among HIV+ Patients in Northern Vietnam (2017) (3)
Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. (2020) (3)
HIV-1 Transmission linkages among persons with incident infection to inform public health surveillance (2021) (3)
Immunologic Reconstitution Through 6 Years in Antiretroviral-Naïve Subjects Treated with Lopinavir/ritonavir (LPV/r) (2005) (3)
Incident sexually transmitted infection as a biomarker for high risk sexual behavior following diagnosis with acute HIV (2014) (3)
Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011 (2013) (3)
Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV (2010) (3)
1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis (2020) (3)
Predictors of Residual Viremia in Patients on Long-term Suppressive Antiretroviral Therapy (2013) (3)
Durable suppression of HIV+ RNA after 2 years of therapy with ABT-378/ritonavir treatment in single protease inhibitor experienced patients (2000) (3)
Types of Stroke Among People Living With HIV in the United States. (2021) (3)
Co-trimoxazole Prophylaxis, Asymptomatic Malaria Parasitemia, and Infectious Morbidity in Human Immunodeficiency Virus–Exposed, Uninfected Infants in Malawi: The BAN Study (2017) (3)
CD4 count at entry into HIV care and at antiretroviral therapy prescription in the US, 2005-2018. (2020) (3)
Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. (2021) (2)
Evaluating the Efficacy of Therapies in COVID-19 Patients. (2020) (2)
Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates (2021) (2)
Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study (2020) (2)
2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis (2019) (2)
HIV Transmission Hotspot Detection Combining Sexual and Phylogenetic Network Analysis (2016) (2)
Brief Report: Insomnia and Risk of Myocardial Infarction Among People With HIV (2022) (2)
AUTHOR'S CORRECTION Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1 (1999) (2)
Dynamics of HIV-specific T cells on long-term ART differ by antigen recognised and by sex (2019) (2)
Near Real-Time Identification of Recent HIV Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by MPID-NGS in North Carolina. (2020) (2)
Supplementary material : Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial (2011) (2)
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection (2022) (2)
Transcriptional Changes in CD8+ T Cells During Antiretroviral Therapy Intensified With Raltegravir (2015) (2)
Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients (2022) (2)
Comparing dynamic monitoring strategies based on evolving CD4 cell counts in virologically suppressed HIV-positive individuals on cART: a prospective observational study in high-income countries (2017) (2)
Racial and ethnic disparities in COVID-19 disease incidence independent of comorbidities, among people with HIV in the US (2021) (2)
Male sex and obesity are associated with residual plasma HIV-1 viremia in persons on long-term antiretroviral therapy. (2020) (2)
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection (2023) (2)
Hematologic, Hepatic, Renal, and Lipid Laboratory Monitoring After Initiation of Combination Antiretroviral Therapy in the United States, 2000–2010 (2013) (2)
Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019 (2020) (2)
Erratum: Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance (Pharmacology and Therapeutics 86(2) (145-170)) (2000) (2)
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial (2022) (2)
Treatment Responses in Antiretroviral Treatment (ART) Naïve Pre-and Post-menopausal HIV-infected Women: An Analysis from ACTG Studies (2009) (1)
Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to Eleven Years. (2020) (1)
HIV in body ̄uids during primary HIV infection: implications for pathogenesis, treatment and public health (1)
CD4CD8 T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection (2012) (1)
Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings (2017) (1)
Track C Epidemiology and Prevention Science (2012) (1)
Risk factors for atrial fibrillation in a multi-center US clinical cohort of people with HIV infection. (2022) (1)
HIV/AIDS Annual Update 2009 (2009) (1)
Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. (2018) (1)
HIV-1 is Transported into the Central Nervous System by Trafficking Infected Cells (2023) (1)
Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy (2020) (1)
Reply to P. De Paoli et al. (2014) (1)
Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US. (2023) (1)
Barriers and Motivators to Participation in Human Immunodeficiency Virus (HIV) Clinical Trials of Persons Living With HIV in the Southern United States (2015) (1)
Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic (2021) (1)
New HIV Drugs (2007) (1)
Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to Eleven Years. (2020) (1)
Mortality for adults entering HIV care under universal early treatment compared to the general US population. (2022) (1)
Comparison of methods to quantify inducible HIV-1 outgrowth (2021) (1)
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials (2018) (1)
Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States (2022) (1)
Class of antiretroviral drugs and anemia risk in the current treatment era (2019) (1)
Reduction in AIDS defining events/deaths with etravirine (ETR; TMC125) compared to placebo: pooled DUET 48-week results (2008) (1)
Age trends in the prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Cameroon: a cross-sectional study (2012) (1)
Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome Among HIV-Infected Individuals In The Center For AIDS Research Network Of Integrated Clinical Systems (2013) (1)
View from the Pipeline : The 2004 Review of Experimental Antiretrovirals (2004) (1)
Mo1383 - Untreated HCV in HIV/HCV Co-Infection; Data from the Trio Network (2018) (1)
Using Primer-ID Deep Sequencing to Detect Recent HIV-1 Infection (2018) (1)
Th2 cytokines are associated with higher levels of intact proviruses on ART (2019) (1)
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19 (2022) (1)
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018 (2020) (1)
Opioid misuse among persons with HIV engaged in care in the Southeastern US (2019) (1)
Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment. (2022) (1)
Feasible Primary HIV Infection Screening: The North Carolina Experience (2003) (1)
Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort (2022) (1)
No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART (2021) (1)
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection (2022) (1)
The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum (2022) (1)
Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. (2023) (1)
Estimating multiple time‐fixed treatment effects using a semi‐Bayes semiparametric marginal structural Cox proportional hazards regression model (2018) (1)
Domestic prevalence of substance use disorders in HIV care settings (2017) (1)
Prevalence and risk of residual viremia after ART in low- and middle-income countries (2021) (1)
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018 (2020) (1)
Evolution of HIV-1 Drug Resistance after Virological Failure of First-line Antiretroviral Therapy in Lusaka, Zambia (2019) (1)
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses (2022) (1)
antiviral agent that may be used in combination with antiretroviral therapy. (2015) (0)
Retesting of Suspected Low-Level Human Immunodeficiency Virus (HIV)-1 Viral Load Blips: A New Paradigm to Prevent Extra Clinic Visits and Unnecessary Patient Anxiety (2016) (0)
796. HIV transmission clusters among people who inject drugs in North Carolina, 2010 to 2021 (2022) (0)
PIN4 IMPACT OF ADHERENCE ON VIRAL SUPPRESSION IN PATIENTS WITH HIV RECEIVING BICTEGRAVIR OR DOLUTEGRAVIR REGIMENS (2020) (0)
New Antiretroviral Agents (2005) (0)
Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015. (2021) (0)
Faculty Opinions recommendation of Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. (2012) (0)
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 (2023) (0)
Acute HIV Infection Portion of the Anti-HIV T Cell Response to T Cells Represent a Significant + CD8+ CD4 (2012) (0)
Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV (2023) (0)
Erratum: Acute HIV revisited: New opportunities for treatment and prevention (Journal of Clinical Investigation (2004) 113, (937-945) DOI:10.1172/JCI200421540) (2006) (0)
Copd And The Risk For Myocardial Infarction By Type In People With Hiv. (2022) (0)
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials (2023) (0)
Correction to: Genetic architecture of cardiometabolic risks in people living with HIV (2021) (0)
Challenging HIV Cases (2016) (0)
Abstract W P399: Magnetic Resonance Imaging Based Cerebral Blood Flow Changes in Asymptomatic Human Immunodeficiency Virus Infected Subjects (2015) (0)
Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV (2022) (0)
Corrigendum to: Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. (2022) (0)
OP 2.7 – 00057 The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells (2022) (0)
Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate. (2018) (0)
Early antiretroviral therapy not associated with higher cryptococcal meningitis mortality in people with HIV in high-income countries: an international collaborative cohort study. (2023) (0)
THU-135-Real-world HCV treatment in HCV-HIV coinfected population: Data from the TRIO network (2019) (0)
Clinical Trials for HIV Cure: How Do We Get There from Here? (2015) (0)
Corrigendum to: The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. (2021) (0)
Short-Cycle Therapy is Short on Ethics. (2021) (0)
Anal cancer incidence in men with HIV who have sex with men: are black men at higher risk? (2021) (0)
HIV and the Heart (2010) (0)
Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy : 96-week Results of AIDS Clinical Trials Group A 5241 ( OPTIONS ) (2019) (0)
Retesting of suspected low-level HIV-1 viral load blips: A new paradigm to prevent extra clinic visits and unnecessary patient anxiety (2016) (0)
Faculty Opinions recommendation of Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. (2012) (0)
Faculty Opinions recommendation of Motivational interviewing for improving outcomes in youth living with HIV. (2012) (0)
Reply to 'pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial' (2012) (0)
Development of frail RISC-HIV: a risk score for predicting frailty risk in the short-term for care of people with HIV. (2023) (0)
Abstract LB-160: Incidence of non-AIDS-defining cancers over time in the post-ART era (2018) (0)
Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial (2011) (0)
Reply to Parikh and Mellors (2012) (0)
Associations between multiple measures of HIV-1 persistence on suppressive antiretroviral therapy. (2022) (0)
F1000Prime recommendation of Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. (2012) (0)
1704. Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) among People Living with Human Immunodeficiency Virus (PLWH) (2020) (0)
Reduction in cerebral oxygen metabolism in subcortical regions may be a biomarker of cognitive decline in people living with human immunodeficiency virus (2021) (0)
Faculty of 1000 evaluation for Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. (2012) (0)
Associations between female birth sex and risk of chronic kidney disease development among people with HIV in the USA: A longitudinal, multicentre, cohort study (2022) (0)
Vaporized Nicotine (E-Cigarette) and Tobacco Smoking Among People With HIV: Use Patterns and Associations With Depression and Panic Symptoms (2022) (0)
Behavioral and clinical factors and Direct Acting Antiviral effectiveness in HCV/HIV co-infection; clinical experience from the TRIO network (2018) (0)
Proportion of patients with any clinical endpoint: pooled 96-week analysis (2009) (0)
77. Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens (2021) (0)
Current Antiretroviral Treatment Among People With Hiv In The Us: Findings From The Cnics Cohort. (2022) (0)
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19 (2023) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Faculty Opinions recommendation of Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. (2012) (0)
718 - Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection; Clinical Experience from the Trio Network (2018) (0)
Abstract 26: Assessing and Refining Cardiovascular Disease Risk Estimation Among Patients with Human Immunodeficiency Virus: Center for Acquired Immunodeficiency Syndrome Research Network of Integrated Clinical Systems (2016) (0)
Effects of different treatment regimens on T cell function in acute HIV infection. (2016) (0)
24 HIV-specific, ex vivo expanded T cell therapy (HXTC) for HIV clearance: feasibility, safety and efficacy (2017) (0)
Clinical and Behavioral Outcomes for Transgender Women Engaged in HIV Care: Comparisons to Cisgender Men and Women in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort. (2023) (0)
Effects of early human immunodeficiency virus infection on cerebral white matter blood flow autoregulation. (2022) (0)
TUPDC0103: Gonorrhea infections diagnosed among persons living with HIV: cross matching surveillance registries to identify potential opportunities for integrated partner services-New York City, Washington D.C., Miami/Dade County and Arizona (2012) (0)
Evaluating the incident user design in the HIV population: incident use versus naive? (2015) (0)
Expert offers help for PI-related heart disease. (2002) (0)
Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19 (2022) (0)
HIV post-treatment controllers have distinct immunological and virological features. (2023) (0)
Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine. (2023) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Start Early: HAART for HIV: Start Early or Wait (2005) (0)
Track B Clinical Science (2012) (0)
Track B Clinical Science (2012) (0)
881. Nasal and Plasma SARS-CoV-2 RNA Levels Predict Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19 (2022) (0)
2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression (2019) (0)
Virus Type 1 Transmission of Human Immunodeficiency Semen : Implications for Sexual Antiretroviral-Drug Concentrations in (1999) (0)
Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A qualitative study (2022) (0)
HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico (2015) (0)
Anal cancer incidence in MSM with HIV (2021) (0)
Corrigendum to: Fusion designs and estimators for treatment effects. (2023) (0)
Reply to Bottanelli et al. (2022) (0)
How clean was the KLEAN trial? – Authors' reply (2006) (0)
Iconographies supplémentaires de l'article : Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial (2011) (0)
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals (2021) (0)
Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections (2017) (0)
349: Effect of Deferred Antiretroviral Therapy on Disease Progression and Survival in Hiv Seroconverters (2005) (0)
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection (2019) (0)
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection (2020) (0)
Characteristics Associated with Response to Antiretroviral Therapy (ART) among People Living with Human Immunodeficiency Virus (PLWH) (2020) (0)
HIV-specific T-cell responses reflect substantive in vivo interactions with infected cells despite long-term therapy (2020) (0)
P011: 91–94% SVR24 in HCV/HIV-1 co-infected patients treated with ombitasvir/paritaprevir/r and dasabuvir with ribavirin (2015) (0)
Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV. (2023) (0)
PP 4.14 – 00173 Antiretroviral therapy repairs CD4 T cell dysregulation in people living with HIV (2022) (0)
550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice (2018) (0)
Development and integration of IPV-4, a patient-reported screening instrument of intimate partner violence for primary and HIV care (2022) (0)
HIV antibody and T cell responses on ART are associated with HIV DNA but not RNA (2017) (0)
Varied Patterns of Decay of Intact HIV-1 Proviruses Over two Decades of Art. (2023) (0)
Abstract WMP55: HIV Viral Load and Stroke Risk (2020) (0)
Do T cells from HIV-infected individuals have normal metabolic function? (2017) (0)
PP 7.8 – 00060 Slowing or Reversal of Decay of Intact Proviruses Over Two Decades of Suppressive ART (2022) (0)
Stable Caloric Intake and Continued Virologic Suppression for Human Immunodeficiency Virus-Positive Antiretroviral Treatment Experienced Women After Switching to Fixed-Dose Combination of Emtricitabine, Tenofovir and Rilpivirine (2015) (0)
1063. Female sex and SARS-CoV-2 Serostatus Predict Nasopharyngeal RNA Clearance during Early COVID-19 (2022) (0)
878. Association between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death for Non-Hospitalized Adults with Mild-to-Moderate COVID-19 (2022) (0)
Amendment history : Corrigendum ( December 2006 ) Acute HIV revisited : new opportunities for treatment and prevention (2018) (0)
2073. Persistent HIV-1 Viremia Despite Intensive Antiviral Therapy Due to Non-responsive Clonal Viral Lineages (2022) (0)
Faculty Opinions recommendation of A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. (2012) (0)
1400. Emergency Department (ED) Use among Persons With HIV (PWH) before and during the COVID-19 Pandemic (2022) (0)
OP 4.6 – 00185 No associations between magnitudes of HIV-specific CTL responses on stable art and subsequent decay of intact proviruses or cell-associated HIV mRNA (2022) (0)
ACE inhibitors and aortic rupture (2006) (0)
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 (2023) (0)
1253. Acceptability and feasibility of long-acting injectable antiretroviral therapy for persons who inject drugs in Vietnam: using the Consolidated Framework on Implementation Research to identify determinants and inform implementation strategies (2022) (0)
Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy (2022) (0)
Correlation ofVirusPolypeptide Structure withAttenuation ofPoliovirus Type1 (1977) (0)
Transcriptional Changes in CD 8 + T Cells During Antiretroviral Therapy Intensi fi ed With Raltegravir (2015) (0)
Abstracts of the 9th HIV Persistence During Therapy Workshop (2019) (0)
F1000Prime recommendation of Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. (2012) (0)
Correction to “Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study” (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joseph J Eron?

Joseph J Eron is affiliated with the following schools:

Harvard University
University of North Carolina at Chapel Hill
Massachusetts General Hospital

Joseph J Eron's Academic­Influence.com Rankings

Why Is Joseph J Eron Influential?

Joseph J Eron's Published Works

Published Works

What Schools Are Affiliated With Joseph J Eron?

Joseph J Eron's AcademicInfluence.com Rankings